[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,72,107,131,168,237,268,293,323,348],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100540341","surgical-approach-to-uterine-septum-100540341",false,"NCT06315582","Surgical Approach to Uterine Septum","Surgical Approach to Uterine Septum: A Randomized Controlled Trial","Inclusion criteria\n\n* Have a confirmed septum (\\>1.0 cm) confirmed with 3D imaging and\u002For MRI\n* 20-44 years old\n\nExclusion criteria\n\n* Known tubal disease\n* Bleeding diastasis\n* No blood thinners\n* No concurrent laparoscopy scheduled\n* Patient with confirmed fibroids over \\>1 cm FIGO (International Federation of Gynecology and Obstetrics) type 1",true,"FEMALE","22 Years","44 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to determine if the use of scissors without electrosurgery is superior to bipolar electrosurgery for resection of uterine septum. The investigators will be comparing procedure-level variables such as operative time, complications, and need for additional procedures.",[28,29,30,31,32],"Uterine Septum","Surgical Complication","Septum; Uterus","Treatment Side Effects","Treatment","RECRUITING","2026-05-28",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":39,"type":37},"2024-03-11",{"date":41,"type":22},"2026-12",{"name":43,"class":44},"Northwestern University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100467293","prehabilitation-for-ovarian-cancer-patients-100467293","NCT05364879","Prehabilitation for Ovarian Cancer Patients","The Impact of Prehabilitation Exercise on Frailty and Treatment Outcomes in Ovarian Cancer Patients","Inclusion Criteria:\n\n* 18 years or older\n* Have a confirmed diagnosis of stage III or IV ovarian cancer\n* Scheduled to receive cytoreductive surgery as part of their treatment plan\n* Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery\n* Be able to attend in-person and\u002For virtual exercise sessions\n* Be fluent in English\n* Have oncologist approval\n\nExclusion Criteria:\n\n* Have already completed surgery\n* Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise\n* Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)","18 Years",{"count":55,"type":22},108,[25],"Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and\u002For receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.",[59,60,61,62,29,63,64],"Prehabilitation","Exercise","Frailty","Ovarian Cancer","Treatment Outcomes","Enhanced Recovery After Surgery",{"date":36,"type":37},{"date":67,"type":37},"2023-01-03",{"date":69,"type":22},"2027-08-31",{"name":71,"class":44},"Nova Scotia Health Authority",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100609100","pre-habilitation-within-eras-protocol-for-gynecologic-oncology-surgery-the-preeras-study-100609100","NCT07210164","Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study","Prehabilitation With Exercise and Immunonutrition (Ocoxin®) in the Perioperative Management of Gynecologic Malignancies Under ERAS Protocol.","Pre_ERAS","Inclusion Criteria:\n\n* Type of gynecological malignancy: endometrial cancer, ovarian cancer, cervical cancer, treated with laparotomy after the decision of the gynecological-oncology unit (positive opinion of the Multidisciplinary Tumor Board - MDT)\n* Patient age: 18 to 85 years\n* General condition of the patient: ASA score I-III\n* Consent to implement the accelerated recovery protocol - Enhanced recovery after surgery (ERAS)\n* Sufficient understanding of the Greek language\n* Provision of signed, after thorough information, consent to participate in the study\n\nExclusion Criteria:\n\n* Women with performance status: ECOG \\>2 and ASA score \\>III\n* Women who have not been informed and have given written consent","85 Years",{"count":82,"type":22},100,[25],"ERAS (Enhanced Recovery After Surgery) protocols are step-by-step care plans that help patients recover faster after surgery. They focus on keeping the body's normal functions, lowering stress from surgery, and supporting a quicker recovery. In gynecologic cancer surgeries, ERAS has been shown to help patients do better, have fewer problems, and leave the hospital sooner.\n\nA prehabilitation program, in combination with ERAS protocols, aims to optimize patients' physical and psychological condition prior to surgery for gynecological cancers. Interventions may include tailored exercise, nutritional support, respiratory training, and psychological preparation. By enhancing baseline fitness and resilience, prehabilitation improves the body's ability to tolerate surgical stress, reduces complications, and facilitates a faster, smoother recovery within the ERAS framework.",[86,87,88,89,90,91,92,29,93,94,95],"ERAS","Compliance","Quality of Life (QOL)","Excercise","Immunonutrition","Post Operative Pain","Laparotomy Patients","Gynaecological Malignancies","Gynaecologic Cancer","Gynaecological Oncology",[59,86,97,90],"Gynecologic Cancers","2025-09-29",{"date":100,"type":37},"2025-10-07",{"date":102,"type":22},"2025-12-01",{"date":104,"type":22},"2029-12-30",{"name":106,"class":44},"Aristotle University Of Thessaloniki",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100566031","a-novel-surgical-irrigation-solution-in-post-mastectomy-reconstruction-evaluating-xperience-100566031","NCT06649890","A Novel Surgical Irrigation Solution in Post-Mastectomy Reconstruction: Evaluating Xperience™","A Randomized Control Trial Evaluating the Efficacy of Xperience™ Surgical Irrigation Solution Versus Dilute Povidone-Iodine in Preventing Surgical Site Infections and Improving Postoperative Outcomes in Implant-Based Breast Reconstruction","Inclusion Criteria:\n\n* Older than 18 years old\n* Willing to comply with all study-related procedures\n* Available for the duration of the study\n* Participants undergoing double mastectomy surgery followed by one of the following: (1) Immediate reconstruction with tissue expander placement, (2) Delayed reconstruction with tissue expander or implant placement, (3) Immediate reconstruction with implant placement, (4) Second-stage reconstruction with tissue expander to implant exchange\n\nExclusion Criteria:\n\n* Participants unable to participate in follow-up visits\n* Participants undergoing unilateral mastectomy\n* Tissue expanders placed by a surgeon outside of the UNC Chapel Hill Hospital System\n* Undergoing autologous reconstruction\n* Participant is unable to provide signed and dated informed consent\n* Unwilling or unable to comply with all study-related procedures.\n* Known history of sensitivity or allergic reaction to any of the components of the Xperience™ irrigation solution or dilute povidone-iodine irrigation\n* Participant with any conditions that would be a contraindication to receiving surgery such as contraindications to general anesthesia\n* Pregnant, planning to become pregnant or breast feeding participants\n* Individuals providing informed consent with any mental impairment or condition that would make them unable to properly consent without use of legally authorized representative (LAR) or additional participant protections.\n* Incarcerated participants",{"count":115,"type":22},224,[25],"Goal of the Clinical Trial:\n\nThe purpose of this clinical trial is to learn whether Xperience™ surgical irrigation solution is more effective than a standard dilute povidone-iodine solution in reducing surgical site infections (SSIs) following implant-based breast reconstruction in female patients, aged 18 and older. It will also assess the safety and overall surgical outcomes when using Xperience™ compared to povidone-iodine.\n\nMain Questions the Study Aims to Answer:\n\n* Does the use of Xperience™ decrease the incidence of surgical site infections compared to povidone-iodine?\n* What are the differences in the rates of premature implant removal due to infection between patients treated with Xperience™ and those treated with povidone-iodine?\n* Are there fewer post-surgical complications with Xperience™ compared to povidone-iodine?\n\nStudy Design:\n\nParticipants in this study will be randomly assigned to receive either Xperience™ or a dilute povidone-iodine solution during their bilateral implant-based breast reconstruction. Only the research team will know which irrgiation is given- the participant will not know.\n\nParticipant Will:\n\n* Undergo the surgical procedure using one of the two irrigation solutions.\n* Receive regular post-operative check-ups to monitor for signs of infection and other complications.\n* Have data collected on any post-surgical complications, the necessity for early implant removal, and overall surgical outcomes.",[119,29,120,121],"Surgical Site Infection","Implant Infection","Implant Complication","2025-08-06",{"date":124,"type":37},"2025-08-07",{"date":126,"type":37},"2025-06-30",{"date":128,"type":22},"2028-06-30",{"name":130,"class":44},"University of North Carolina, Chapel Hill",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":140,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100597485","implant-based-breast-reconstruction-in-post-bariatric-women---a-registry-based-national-study-100597485","NCT07059104","Implant-based Breast Reconstruction in Post-bariatric Women - a Registry-based National Study","Implant-based Breast Surgery and Reconstruction Following Bariatric Surgery: an Observational Register-based Study on Prevalence and Risk Factors for Surgical Complications","Inclusion Criteria:\n\nInclusion in Soreg and thereafter inclusion in either BRIMP or NKBC\n\nExclusion Criteria:\n\n\\-",{"count":139,"type":22},20000,"10 Years","OBSERVATIONAL","The goal of this national registry-based study is to investigate the prevalence of reconstructive breast surgery and risk factors for surgical complications in women who have had weight loss surgery previously. The main questions it aims to answer are:\n\n1. What is the perceived need for breast implants after weight loss surgery, described as the proportion who have breast implants, and what characteristics, in terms of demographics and surgical details, do the operated women have?\n2. In women who have breast enlargement or breast enlargement combined with a lift, are there any differences between the women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example skin incision and choice of implant (for example texture, shape, size)?\n3. In women who have delayed breast reconstruction after breast cancer, that is have had their breast\u002Fs reconstructed in a separate operation, are there any differences between the women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example in technique used (autologous versus implant-based, choice of implant, such as texture, shape and size), and timing of the surgery? Immediate breast reconstruction is defined as performed at the same time as the mastectomy, and delayed as an operation performed later in a separate operation.\n4. In women who have immediate breast reconstruction after breast cancer?, that is have a breast reconstruction at the same time as the mastectomy, are there any differences between the women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example in technique used (autologous versus implant-based, choice of implant, such as texture, shape and size), and timing of the surgery? Immediate breast reconstruction is defined as performed at the same time as the mastectomy, and delayed as an operation performed later in a separate operation.\n5. In women who have risk reducing mastectomies, are there any differences between he women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example in technique used (autologous versus implant-based, choice of implant, such as texture, shape and size), and timing of the surgery? Immediate breast reconstruction is defined as performed at the same time as the mastectomy, and delayed as an operation performed later in a separate operation.\n6. Are there any identifiable risk factors for complications after breast reconstructive surgery, specific to the women who have had weight loss surgery and other women?\n\nResearchers will compare the patients to women who have the same type of reconstructive breast surgery but have not had bariatric surgery previously.\n\nThe study will use prospectively collected data from seven registers: The Scandinavian Obesity Surgery Register (SOReg), The Swedish Breast Implant Register (BRIMP), the Swedish National Quality Register for Breast Cancer (NKBC), the Swedish National Diabetes Register (NDR), Statistics Sweden (SCB), the Swedish inpatient register, and the Swedish National Prescribed Drug Register.",[144,145,146,147,148,29,149,150],"Breast Cancer","Breast Reconstruction","Bariatric Surgery","Breast Implant","Breast Implant Infection","Mastopexy","Weight Loss",[152,153,154,155,156,157],"plastic surgery","breast augmentation","breast implant","augmentation mastopexy","complications","post-bariatric reconstruction","2025-07-10",{"date":160,"type":37},"2025-07-16",{"date":162,"type":37},"2025-01-01",{"date":164,"type":22},"2028-12-31",{"name":166,"class":167},"Vastra Gotaland Region","OTHER_GOV",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":176,"minAge":4,"maxAge":4,"enrollmentInfo":177,"targetDuration":179,"studyType":141,"phases":4,"briefSummary":180,"conditions":181,"keywords":201,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":45},"100230679","a-real-world-registry-of-chronic-wounds-and-ulcers-100230679","NCT02280733","A Real-World Registry of Chronic Wounds and Ulcers","A Longitudinal, Real World, Observational Registry of Chronic Wounds and Ulcers and the Patients Who Have Them","WOUNDJOURNEY","Inclusion Criteria:\n\n* Presence of one or more chronic wounds or ulcers of any etiology\n* Wound or ulcer must be treated at a participating site (which can be a hospital outpatient department, office, mobile practitioner, in the home setting, skilled nursing, etc.)\n* Care must be documented using the purpose-built, wound-specific structured electronic health record (EHR) or electronic data capture (EDC) system\n* All ages, including infants and patients aged 90 years or older (reported in aggregate in accordance with HIPAA de-identification standards)\n* All sexes and gender identities\n* All wound types and severities, including multiple wounds per patient\n\nExclusion Criteria:\n\n-None (the registry includes all eligible patients treated at participating sites without sampling or exclusion criteria)","ALL",{"count":178,"type":22},300000,"5 Years","WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers. Data are collected during routine care from over 1,400 clinicians across the USA and Puerto Rico using a highly structured certified electronic health record (EHR) or electronic data capture (EDC) system. Data are transmitted daily to the U.S. Wound Registry (USWR), a CMS-recognized Qualified Clinical Data Registry (QCDR). The registry captures real-time, research-ready data on patient demographics, comorbidities, wound characteristics, standard-of-care treatments, complications, and advanced therapeutics. It supports robust, fit-for-purpose real-world evidence generation by enabling risk-adjusted outcome analysis, comparative effectiveness research, and quality improvement across diverse sites of care.",[182,183,184,185,186,187,188,189,190,29,191,192,193,194,195,196,197,198,199,200],"Diabetic Foot","Pressure Ulcer","Surgical Wound Dehiscence","Vasculitis","Skin Ulcer","Leg Ulcer","Pyoderma","Peripheral Arterial Disease","Lymphedema","Venous Leg Ulcers (VLUs)","Calciphylaxis","Sickle Cell Ulcer","Pressure Ulcer (PU)","Diabetic Foot Ulcers (DFUs)","Pressure Injury","Arterial Ulcers","Soft Tissue Radionecrosis (STRN)","Traumatic Wounds","Chronic Ulcer",[202,203,204,205,206,207,208,209,183,196,210,211,29,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229],"Qualified Clinical Data Registry","Quality Measures","Clinical Data Research Network","Real world data","chronic wounds","chronic ulcers","Diabetic Foot Ulcer","Venous Leg Ulcer","Arterial Ulcer","Traumatic Wound","Pyoderma Gangrenosum","Advanced Wound Care","Skin Substitutes","CAMPs","CTPs","Negative Pressure Wound Therapy","NPWT","Collagen Dressings","Compression Therapy","Hyperbaric Oxygen Therapy","Wound Debridement","Real-World Evidence","Comparative Effectiveness","Wound Healing","Amputation","Electronic Health Record (EHR)","Debridement","Standard of Care",{"date":160,"type":37},{"date":232,"type":37},"2005-01-01",{"date":234,"type":22},"2030-01",{"name":236,"class":44},"U.S. Wound Registry",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":253,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100532684","incidence-of-residual-neuromuscular-blockade-in-fraility-in-oncogynae-surgery-100532684","NCT06216002","Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery","Incidence of Residual Neuromuscular Blockade in Patients With Frailty Undergoing Gynecologic Cancer Surgery","FIGO","Inclusion Criteria:\n\n* Age \\>,= 18 years\n* Patients undergoing elective gynecologic-oncology surgery\n\nExclusion Criteria:\n\n* Unable to communicate Thai\n* Unable to understand the questionnaire\n* Preexisting neuromuscular disease\n* Preexisting disease involved wrist that may affect the nerve stimulator examination",{"count":246,"type":22},622,[25],"Frailty among patients undergoing surgery is strongly associated with an elevated risk of adverse perioperative outcomes, heightened incidence of postoperative complications, increased mortality rates, and prolonged hospital length of stay. Our focus centers on investigating the frailty index in the context of complications experienced by patients undergoing oncologic gynecology surgery. The principal objective of this research is to elucidate the extent to which residual neuromuscular blocking agents are linked to frailty.",[61,250,251,252,29],"Neuromuscular Blockade","General Anesthetic Drug Adverse Reaction","Gynecologic Cancer",[254,255,256,257,258],"neuromuscular blocking agents","frailty","gynecologic oncology","surgery","anesthetic complications","2025-05-07",{"date":261,"type":37},"2025-05-08",{"date":263,"type":37},"2024-01-02",{"date":265,"type":22},"2025-12-31",{"name":267,"class":44},"Mahidol University",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":176,"minAge":53,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":45},"100468312","continuous-wireless-monitoring-of-vital-signs-and-automated-alerts-in-participants-at-home-and-during-hospitalization-100468312","NCT05378139","Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","WARD Prospective Study - Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","Inclusion Criteria:\n\n* Adult participants (≥18 years)\n* Patients assessed by the clinical staff as having an acute condition with risk for clinical deterioration and being either at home (with no apparent need for hospitalization), and\u002For in hospital OR\n* Patients at either at home before, in-hospital and\u002For after hospitalization for elective major surgery, defined as surgery lasting more than one hour under general- or regional anaesthesia\n\nExclusion Criteria:\n\n* The participant expected not to cooperate with study procedures.\n* Allergy to plaster or silicone.\n* Having pacemaker or Implantable Cardioverter Defibrillator (ICD) device.\n* Inability to give informed consent.",{"count":276,"type":22},3095,"The primary aim of this study is to test and assess the implementation and effectiveness of continuous wireless vital signs monitoring with real-time alerts on:\n\nThe frequency of patients monitored with adequate data quality as adequate clinical user satisfaction in the initial versus the last part of the trial (primary outcome).",[29,279,280,281,282,283],"Pulmonary Disease","Hematologic Diseases","Oncology","Cardiac Disease","Infections","2025-04-08",{"date":286,"type":37},"2025-04-11",{"date":288,"type":37},"2021-02-01",{"date":290,"type":22},"2025-12-22",{"name":292,"class":44},"University Hospital Bispebjerg and Frederiksberg",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":176,"minAge":53,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":312,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100556136","usability-of-pericardial-flushing-with-the-haermonics-pure-system-after-cardiac-surgery-100556136","NCT06521164","Usability of Pericardial Flushing with the Haermonics Pure System After Cardiac Surgery","USEPURE","Inclusion Criteria:\n\n1. Adult patients (≥18yrs and weight ≥40kg) undergoing cardiothoracic surgery (CABG and\u002For valve surgery, elective aortic surgery, Bentall procedure, ascending aorto\u002Faortic arch replacement) with the use of cardiopulmonary bypass\n2. Patient has been informed of the nature of the clinical investigation and is willing and able to give written informed consent for investigation participation\n\nExclusion Criteria:\n\n1. Euroscore II \\> 20%\n2. Emergent procedures\n3. Complication during surgery which is life threatening and\u002For requires another surgical intervention\n4. Minimal invasive cardiac surgery procedures (e.g. minithoracotomy and hemisternotomy)\n5. Thoraco-abdominal surgery, or intraoperative injury to the diaphragm leading to an open connection between the thoracic and abdominal cavity\n6. Participation in any study involving an investigational drug or device\n7. Patient is pregnant or nursing\n8. Inability to understand study information",{"count":301,"type":22},65,[25],"The goal of this clinical trial is to evaluate the usability of the Haermonics Pure system in patients undergoing a cardiac surgery procedure with the use of cardiopulmonary bypass.\n\nAll measurements and interventions are standard of care, except pericardial flushing with the Haermonics Pure system.",[305,29],"Surgical Blood Loss",[307,308,309,310,311],"cardiac surgery","therapeutic irrigation","postoperative bleeding","chest tubes","Haermonics Pure System","NOT_YET_RECRUITING","2025-03-11",{"date":315,"type":37},"2025-03-14",{"date":317,"type":22},"2025-10-01",{"date":319,"type":22},"2026-05",{"name":321,"class":322},"Haermonics BV","INDUSTRY",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":176,"minAge":53,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":45},"100536867","phase-4-the-effect-of-local-application-of-tranexamic-acid-versus-placebo-on-postoperative-complications-in-plastic-surgery-100536867","NCT06270407","The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery","The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery - A Multicenter Randomized Controlled Trial","TRANOP","Inclusion Criteria:\n\n* Patients are eligible to be included in the study only if all of the following criteria apply:\n\n  1. They are to undergo a surgical procedure within the field of plastic surgery where the procedure involves use of topical TXA at the participating center.\n  2. They are over 18 years of age and capable of independently providing informed consent\n  3. They have received adequate oral and written information about the study and signed the informed-consent form\n\nExclusion Criteria:\n\n* Patients with known allergy to tranexamic acid. Insufficient knowledge of national language or English.",{"count":332,"type":22},3000,[334],"PHASE4","Study objective:\n\nThis is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or seroma, or if it may increase the risk of blood clots.\n\nEligible patients:\n\nPatients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery.\n\nStudy intervention:\n\nParticipants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules.",[29],[338],"tranexamic acid postoperative bleeding infection wound rupture seroma thromboembolism","2024-12-02",{"date":341,"type":37},"2024-12-04",{"date":343,"type":37},"2024-10-01",{"date":345,"type":22},"2029-12-31",{"name":347,"class":44},"St. Olavs Hospital",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":176,"minAge":53,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":357,"conditions":358,"keywords":363,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":45},"100555598","gastrointestinal-dysfunction-in-aortic-surgery-patients-100555598","NCT06514170","Gastrointestinal Dysfunction in Aortic Surgery Patients","Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.","Inclusion Criteria:\n\n* 18 years of age or older.\n* Patients after surgical interventions (elective or urgency) on the aorta with cardiopulmonary bypass.\n* Invasive mechanical ventilation expected to be required more than 48 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under mechanical ventilation with pre-existing gastrointestinal issues.\n* Diagnosis of adult congenital heart disease.\n* Ongoing pregnancy or lactation period.\n* Simultaneous participation in another clinical study involving experimental therapy.\n* Presence of chronic intestinal disease.\n* Previous gastrointestinal conditions detected during nutritional screening.",{"count":356,"type":22},114,"The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary \\[calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)\\] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.",[359,360,361,362,29],"Aortic Aneurysm","Gastrointestinal Dysfunction","Aortic Diseases","Enteral Feeding Intolerance",[364,365,366],"Gastrointestinal dysfunction","Aortic diseases","Aorta surgery","2024-07-23",{"date":369,"type":37},"2024-07-24",{"date":367,"type":37},{"date":372,"type":22},"2026-06",{"name":374,"class":44},"Instituto Nacional de Cardiologia Ignacio Chavez"]